Karzinomprophylaxe

W. Schmiegel; C. Pox; A. Kroesen

doi:10.1055/s-2004-813513

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2004; 42(9): 1021-1025
DOI: 10.1055/s-2004-813513

Leitlinien

Karzinomprophylaxe

Cancer PreventionW. Schmiegel¹ , C. Pox¹ , A. Kroesen²

¹Ruhr-Universität Bochum, Medizinische Universitätklinik, Knappschaftskrankenhaus, Bochum
²Chirurgische Klinik I, Charité, Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin

Abstract

Full Text

References

Literatur

1 Gilat T, Fireman Z, Grossman A. et al . Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. Gastroenterology. 1988; 94 870-877 (IIa)
2 Gyde S N, Prior P, Allan R N. et al . Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut. 1988; 29 206-217 (IIa)
3 Eaden J A, Abrams K R, Mayberry J F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48 526-535 (IIa)
4 Soetikno R M, Lin O S, Heidenreich P A. et al . Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002; 56 48-54 (IIa)
5 Ekbom A, Helmick C, Zack M. et al . Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990; 323 1228-1233 (IIb)
6 D’Haens G R, Lashner B A, Hanauer S B. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol. 1993; 88 1174-1178 (III)
7 Broome U, Lofberg R, Veress B. et al . Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995; 22 1404-1408 (IIa)
8 Porschen R, Holzmann K, Klump B. et al .The role of flow cytometry in surveillance strategies in patients with ulcerative colitis. Emmrich J, Liebe S, Stange EF Innovative concepts in inflammatory bowel diseases Boston, London; Kluwer Academic Publishers 1999: 243-253 (IIa)
9 Holzmann K, Klump B, Borchard F. et al . Flow cytometric and histologic evaluation in a large cohort of patients with ulcerative colitis: correlation with clinical characteristics and impact on surveillance. Dis Colon Rectum. 2001; 44 1446-1455 (IIb)
10 Heuschen U A, Heuschen G, Stern J. Backwash ileitis in ulcerative colitis - new aspects in the assessment of the disease 1997, 245 - 249. Andus T, Goebell H, Layer P, Schölmerich J Inflammatory bowel diseases - from bench to bedside Dordrecht, Boston, London; Kluwer Academic Publishers 1997: 245-249 (III)
11 Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol. 1996; 91 44-48 (III)
12 Rutter M, Saunders B, Wilkinson K. et al . Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126 451-459 (IIb)
13 Sugita A, Sachar D B, Bodian C. et al . Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut. 1991; 32 167-169 (III)
14 Mellemkjaer L, Olsen J H, Frisch M. et al . Cancer in patients with ulcerative colitis. Int J Cancer. 1995; 60 330-333 (IIa)
15 Mir-Madjlessi S H, Farmer R G, Easley K A. et al . Colorectal and extracolonic malignancy in ulcerative colitis. Cancer. 1986; 58 1569-1574 (IIb)
16 Prior P, Gyde S N, Macartney J C. et al . Cancer morbidity in ulcerative colitis. Gut. 1982; 23 490-497 (III)
17 Wee A, Ludwig J, Coffey R J Jr. et al . Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum Pathol. 1985; 16 719-726 (IV)
18 Ahrendt S A, Pitt H A, Nakeeb A. et al . Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Surg. 1999; 3 357 - 367; discussion 367 - 368 (III)
19 Pinczowski D, Ekbom A, Baron J. et al . Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology. 1994; 107 117-120 (III)
20 Moody G A, Jayanthi V, Probert C S. et al . Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996; 8 1179-1183 (IIb)
21 Eaden J, Abrams K, Ekbom A. et al . Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000; 14 145-153 (IIa)
22 Tung B Y, Emond M J, Haggitt R C. et al . Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001; 134 89-95 (IIb)
23 Pardi D S, Loftus E V Jr, Kremers W K. et al . Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003; 124 889-893 (IIb)
24 Biasco G, Zannoni U, Paganelli G M. et al . Folic acid supplementation and cell kinetics of rectal mucosa in patients with ulcerative colitis. Cancer Epidemiol Biomarkers Prev. 1997; 6 469-471 (Ib)
25 Lashner B A, Heidenreich P A, Su G L. et al . Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology. 1989; 97 255-259 (III)
26 Lashner B A, Provencher K S, Seidner D L. et al . The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology. 1997; 112 29-32 (III)
27 Fiedler L, Rubin P, Korelitz B. Does folate supplementation really protect from dysplasia and cancer in ulcerative colitis? a case control study. Gastroenterology. 1993; 104 A546 (III)
28 Choi P M, Nugent F W, Schoetz D J Jr. et al . Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology. 1993; 105 418-424 (III)
29 Connell W R, Talbot I C, Harpaz N. et al . Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut. 1994; 35 1419-1423 (IIb)
30 Giardiello F M, Gurbuz A K, Bayless T M. Colorectal cancer in ulcerative colitis: effect of a cancer prevention strategy on survival. Gastroenterology. 1993; 104 A502 (III)
31 Jablonska M. Management of cancer surveillance in ulcerative colitis. Gut. 1995; 37 (Suppl. 2) A90 (III)
32 Karlen P, Kornfeld D, Brostrom O. et al . Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut. 1998; 42 711-714 (III)
33 Melville D M, Jass J R, Shepherd N A. et al . Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology. 1988; 95 668-675 (IIa)
34 Lim C H, Dixon M F, Vail A. et al . Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut. 2003; 52 1127-1132 (IIb)
35 Dixon M F, Brown L J, Gilmour H M. et al . Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology. 1988; 13 385-397 (Ib)
36 Eaden J, Abrams K, McKay H. et al . Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol. 2001; 194 152-157 (IIb)
37 Greenstein A J, Sachar D B, Smith H. et al . Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology. 1979; 77 290-294 (IIb)
38 Connell W R, Lennard-Jones J E, Williams C B. et al . Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology. 1994; 107 934-944 (IIa)
39 Grundfest S F, Fazio V, Weiss R A. et al . The risk of cancer following colectomy and ileorectal anastomosis for extensive mucosal ulcerative colitis. Ann Surg. 1981; 193 9-14 (III)
40 Kurtz L M, Flint G W, Platt N. et al . Carcinoma in the retained rectum after colectomy for ulcerative colitis. Dis Colon Rectum. 1980; 23 346-350 (IV)
41 Kiesslich R, Fritsch J, Holtmann M. et al . Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003; 124 880-888 (Ib)
42 Fleischer D E. Chromoendoscopy and magnification endoscopy in the colon. Gastrointest Endosc. 1999; 49 S45-S49 (III)
43 Heinzlmann M, Lang S M, Neynaber S. et al . Screening for p53 and K-ras mutations in whole-gut lavage in chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002; 14 1061-1066 (IIb)
44 Markowitz J, McKinley M, Kahn E. et al . Endoscopic screening for dysplasia and mucosal aneuploidy in adolescents and young adults with childhood onset colitis. Am J Gastroenterol. 1997; 92 2001-2006 (III)
45 Rubin C E, Haggitt R C, Burmer G C. et al . DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology. 1992; 103 1611-1620 (Ib)
46 Taylor B A, Pemberton J H, Carpenter H A. et al . Dysplasia in chronic ulcerative colitis: implications for colonoscopic surveillance. Dis Colon Rectum. 1992; 35 950-956 (III)
47 Bernstein C N, Shanahan F, Weinstein W M. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet. 1994; 343 71-74 (III)
48 Ullman T, Croog V, Harpaz N. et al . Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003; 125 1311-1319 (III)
49 Befrits R, Ljung T, Jaramillo E. et al . Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum. 2002; 45 615-620 (III)
50 Provenzale D, Kowdley K V, Arora S. et al . Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology. 1995; 109 1188-1196 (III)
51 Engelsgjerd M, Farraye F A, Odze R D. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology. 1999; 117 1288-1294; discussion 1488 - 1491 (III)
52 Rubin P H, Friedman S, Harpaz N. et al . Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology. 1999; 117 1295-1300 (III)
53 Rozen P, Baratz M, Fefer F. et al . Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis. Gastroenterology. 1995; 108 1361-1370 (III)

Prof. Dr. W. Schmiegel

Ruhr-Universität Bochum, Medizinische Universitätsklinik, Knappschaftskrankenhaus

In der Schornau 25

44892 Bochum

Phone: ++ 49/2 34/2 99 34 00

Fax: ++ 49/2 34/2 99 34 09

Email: meduni-kkh@ruhr-uni-bochum.de